About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
The Clinical Significance of HER2+ Breast Cancer and Opportunities for Improved Outcomes
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
A
Treatment Strategies for Leptomeningeal Disease in HER2+ mBC: Addressing Unmet Needs
By
Alessia Pellerino
2 Videos
101 views
August 29, 2024
0 Comments
Login to view comments.
Click here to Login
13:28
Stanford Medicine
ADCs in HR+ Advanced/Metastatic BC
Feat.
M. Dolezal
20:46
Miami Cancer Institute Precision Oncology Symposium
HER2 Targeted Treatments in Lower BC Expression Ranges
Feat.
I. Krop
21:20
Dana-Farber Cancer Institute
Older Adults With Breast Cancer: Research Updates
Feat.
R. Freedman
23:07
Keck School of Medicine of USC
2024 Updates on the Future of ADCs in Breast Cancer
Feat.
C. Geyer
20:31
OncoAlert
HER2+ mBC: Year-in-Review Including DESTINY Breast-03 & HER2CLIM…
Feat.
S. Graff
05:02
Total Health
CNS Metastasis in Breast Cancer: Surgery & Radiation Considerati…
Feat.
C. Santa-Maria
12:54
Total Health
Antibody Drug Conjugates: Highlights in Breast Cancer
Feat.
K. Kalinsky
19:34
Keck School of Medicine of USC
Breast Cancer Oligometastases and Beyond
Feat.
S. Chmura
15:26
Dana-Farber Cancer Institute
Antibody Drug Conjugates Highlights - mBC Series
Feat.
H. Burstein
29:40
Insights from 2023 SABCS
Year in Review: Metastatic Breast Cancer
Feat.
M. Mac Gregor
03:28
Total Health
62 y/o With HER2+ mBC Who Underwent 2L TDXd Therapy: Case Presentati…
Feat.
P. Sharma,
M. Telli,
K. Kalinsky
21:31
Insights from ESMO Breast 2024 Annual Meeting
ESMO Breast 2024 Summary: "Community Oncologists Highlights&quo…
Feat.
S. Tolaney,
H. Rugo
12:07
Sara Tolaney
ESMO 2024 Noteworthy Abstracts in Breast Cancer
Feat.
H. Rugo
13:05
V.K. Gadi
Key Updates and Insights on HER2+ Breast Cancer
19:30
Elisa Agostinetto
The Evolving Landscape of Treatment Options in HER2+ mBC
04:04
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "Updated Survival Data in DESTINY-Breast03…
Feat.
E. Hamilton
10:31
Sarah Premji
Treatment Selection in 2L for HER2+ MBC: Updated Guidelines, Safety …
21:01
Insights from ESMO Breast 2024 Annual Meeting
ESMO Breast 2024 Panel Discussion: "Key Updates in Breast Cance…
Feat.
S. Tolaney,
H. Rugo
11:57
V.K. Gadi
Clinical Guidance on the Management and Monitoring of T-DXd-Related …
10:09
Insights from ESMO Breast 2024 Annual Meeting
ESMO Breast 2024 Insights: "Pooled Analysis of T-DXd Retreatmen…
Feat.
H. Rugo
12:13
UChicago Medicine
Trastuzumab Deruxtecan in HER2+ mBC
Feat.
H. Rugo
17:48
MSKCC 2nd Annual Symposium on Advanced Therapeutics for Brain Metastasis
Frontiers in Breast Cancer Brain Metastasis: ADC Effectiveness in th…
Feat.
S. Modi
20:19
MSKCC 2nd Annual Symposium on Advanced Therapeutics for Brain Metastasis
Chemoprevention in Brain Mets: Breast Cancer Perspective
Feat.
A. Zimmer